Clinical Report: Evaluation of a New Prognostic Risk Assessment Tool (CHIP Score)

Overview

This study evaluates the CHIP Score's predictive efficacy for major adverse cardiovascular and cerebrovascular events (MACCE) in NSTE-ACS patients. The analysis involved 348 individuals and aims to address the risk assessment gap for complex high-risk patients undergoing interventional treatment.

Background

The management of Complex High-Risk and Indicated Patients (CHIP) is critical due to their increased risk of adverse outcomes during interventional procedures. Current risk scoring systems do not adequately address the unique challenges faced by these patients, necessitating the development of the CHIP Score. This study seeks to validate the CHIP Score's effectiveness in predicting long-term outcomes in a specific patient population.

Data Highlights

Key Findings

• The CHIP Score incorporates patient, procedural, and vascular factors for risk assessment.
• 348 NSTE-ACS patients were analyzed to evaluate the CHIP Score's predictive ability.
• Patients were stratified into four groups based on their CHIP Score.
• The study aims to identify risk factors associated with MACCE in CHIP patients.
• Long-term prognosis of patients using the CHIP Score remains to be validated in larger cohorts.

Clinical Implications

The CHIP Score may serve as a valuable tool for clinicians in assessing the risk of MACCE in high-risk NSTE-ACS patients. Understanding the stratification of risk factors can guide treatment decisions and improve patient outcomes during interventional procedures.

Conclusion

The CHIP Score represents a promising advancement in the risk assessment of complex high-risk patients. Further validation in diverse populations is essential to enhance its clinical utility.

Related Resources & Content

1. Kirtane et al., JACC: Cardiovascular Interventions, 2022 -- Development of the CHIP Score
2. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes - Professional Heart Daily | American Heart Association
3. High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation - PubMed
4. Clinical Research in Cardiology — Assessing Patients with Suspected NSTE-ACS in the Observation Zone: A Study on the GRACE 1.0 Score and Biomarker Panel for Enhanced Risk Stratification and Management
5. Clinical Research in Cardiology — Comparison of GRACE Risk Scores and High-Sensitivity Troponin for Determining Timing of Coronary Angiography in Non-ST-Elevation Acute Coronary Syndromes
6. Clinical Research in Cardiology — Impact of Coronary No-Reflow on Clinical Outcomes in Acute Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention with Modern Drug-Eluting Stents and Third-Generation P2Y12 Inhibitors
7. 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes
8. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes - Professional Heart Daily | American Heart Association
9. High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the ESC Working Group on Cardiovascular Surgery - PubMed